Compound 19A8.8

Compound 19A8.8 is a cyclic peptide derived from a CD36 protein fragment. Compound 19A8.8 inhibits the TGF-β/Smad3 signaling pathway by suppressing the interaction between TSP1 and CD36. Compound 19A8.8 has no obvious cytotoxicity. Compound 19A8.8 can be used for research on colon injury and fibrosis[1].

Product Specifications

UNSPSC

12352209

Target

TGF-beta/Smad; TGF-β Receptor

Related Pathways

Stem Cell/Wnt; TGF-beta/Smad

Field of Research

Neurological Disease

Smiles

O=C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](C(C)C)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCC(N)=O)C(N[C@H]1CC(O)=O)=O)=O)=O)=O)=O)[C@H](CCCCN)NC1=O

Molecular Formula

C35H60N12O13

Molecular Weight

856.92

References & Citations

[1]Zhang W, et al. Design and discovery of novel cyclic peptides as TSP1-CD36 interaction inhibitors for intestinal fibrosis treatment. Bioorg Chem. 2025 Aug;163:108667.